AbbVie

• 8-KNegativeEarningsGuidance loweredImpairment / charge

  Filed Oct 5

  Acquired IPR&D and milestone expenses lower Q3 and FY2026 adjusted EPS guidance.

• 8-KGuidance reaffirmedImpairment / chargeDeal completed

  Filed Sep 3

  Apogee acquisition closes, adding zumilokibart to the immunology pipeline but diluting near-term adjusted EPS.

• 8-KDebt financing

  Filed Aug 18

  Senior notes issuance funds part of the planned Apogee Therapeutics acquisition; specified notes must be redeemed if the deal is abandoned.

• 8-KDebt financing

  Filed Aug 5

  Senior-note offering will help fund the Apogee acquisition and reduce acquisition term-loan commitments.

• 10-QQ2 FY2026Positive

  Filed Aug 3

  Skyrizi and Rinvoq growth more than offset Humira’s biosimilar decline; the proposed Apogee deal would expand the immunology pipeline.

  • Revenue$17.0BYoY +10.2%
  • Net income$3.6BYoY +285.2%

• 8-KEarningsGuidance loweredImpairment / charge

  Filed Jul 31

  Proposed Apogee acquisition trims FY2026 adjusted EPS guidance on expected dilution, partly offset by operating overperformance.

• 8-KNegativeEarningsGuidance loweredImpairment / charge

  Filed Jul 6

  Acquired IPR&D and milestone costs drive cuts to Q2 and FY2026 adjusted EPS guidance.

• 8-KPositiveDeal pending

  Filed Jun 22

  Deal to acquire Apogee would add zumilokibart for atopic dermatitis and APG273 for asthma to the immunology pipeline.

• 8-KShareholder vote

  Filed May 12

  Proposal to eliminate supermajority voting failed despite 98.9% of votes cast in favor.

• 10-QQ1 FY2026

  Filed May 8

  Skyrizi and Rinvoq more than offset Humira’s decline, but contingent-consideration expense pulled GAAP earnings down despite operating growth.

  • Revenue$15.0BYoY +12.4%
  • Net income$695.0MYoY −46.0%

• 8-KPositiveEarningsGuidance raisedImpairment / charge

  Filed Apr 29

  Skyrizi and Rinvoq drove immunology growth; FY2026 adjusted EPS guidance raised.

• 8-KNegativeEarningsGuidance loweredImpairment / charge

  Filed Apr 3

  Acquired in-process R&D and milestone expenses lower Q1 and FY2026 adjusted EPS guidance.

• 8-KDebt financing

  Filed Mar 4

  Completed a seven-tranche unsecured senior-note offering, combining floating- and fixed-rate debt with maturities extending to 2066.

• 8-KDebt financing

  Filed Feb 26

  Seven-tranche senior note sale targets repayment of the term loan due May 2026, with remaining proceeds for general corporate purposes.

• 10-KFY2025PositiveImpairment / charge

  Filed Feb 20

  Skyrizi and Rinvoq more than offset Humira’s biosimilar losses; acquisition-related charges and a tax-rate reversal kept net earnings flat.

  • Revenue$61.2BYoY +8.6%
  • Net income$4.2BYoY −1.2%

• 8-KPositiveEarningsNew guidanceImpairment / charge

  Filed Feb 4

  Skyrizi and Rinvoq led growth; a U.S. investment agreement provides exemptions from tariffs and future pricing mandates.

• 8-KNegativeEarningsGuidance loweredImpairment / charge

  Filed Jan 7

  Acquired in-process R&D and milestone expenses lower Q4 and FY2025 adjusted EPS guidance.

Coverage: 10-K filings filed since Feb 20, 2026; 10-Q since May 8, 2026; 8-K since Jan 7, 2026.

Request longer coverage

Company data: Wikidata Q14662364